Response to brolucizumab treatment for refractory serous pigment epithelial detachment secondary to polypoidal choroidal vasculopathy

BMC Ophthalmology

Research

Zeeyoon Byun¹  Mingui Kong²  Don-Il Ham³  Seung Wan Nam³ 

[1] Department of Ophthalmology, Hangil Eye Hospital, 35 Bupyeong-daero, Bupyeong-gu, 21388, Incheon, Republic of Korea;Department of Ophthalmology, Hangil Eye Hospital, 35 Bupyeong-daero, Bupyeong-gu, 21388, Incheon, Republic of Korea;Department of Ophthalmology, College of Medicine, Catholic Kwandong University, Incheon, Korea;Department of Ophthalmology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea;

关键词: Age-related macular degeneration;    Brolucizumab;    Optical coherence tomography;    Pigment epithelial detachment;    Polypoidal choroidal vasculopathy;   

DOI  :  10.1186/s12886-022-02711-5

 received in 2022-10-21, accepted in 2022-11-28,  发布年份 2022

来源: Springer

【 摘 要 】

PurposeTo report the efficacy and safety of brolucizumab in the treatment of refractory serous pigment epithelial detachment (PED) secondary to polypoidal choroidal vasculopathy (PCV).MethodsTwenty-six eyes of 26 patients were included. Intravitreal brolucizumab 6.0 mg was administered, followed by pro re nata (PRN) retreatment at monthly follow-ups. All patients underwent spectralis domain optical coherence tomography (SD-OCT), fluorescein angiography, and indocyanine green angiography before the first brolucizumab injection. SD-OCT was repeated at follow-up visits. The height and width of the serous PEDs, measured using SD-OCT, were analyzed.ResultsThe number of previous anti-VEGF injections was 12.3 ± 15.0. During brolucizumab treatment, anatomical improvement was achieved and maintained in the height and width of the PEDs (p < 0.05). However, the visual outcome did not improve significantly (p > 0.05). A good response was achieved in 69.2% of eyes at 1 month and at the last visit. Relapse and complete resolution were observed in 27.8 and 23.1% of patients, respectively. The number of brolucizumab injections was 2.00 ± 0.85. Intraocular inflammation, vascular obstruction, and retinal pigment epithelial tears were not observed.ConclusionIntravitreal brolucizumab may be an effective and safe treatment option for refractory serous PEDs in patients with PCV.

【 授权许可】

CC BY   
© The Author(s) 2022

【 图 表 】

Fig. 6

Fig. 2

Fig. 4

12902_2022_1244_Article_IEq22.gif